Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report
Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are limited, no case has been reported. We describe...
Gespeichert in:
| Veröffentlicht in: | Medical journal of Indonesia 2020-12, Vol.29 (4), p.427-30 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 4 |
| container_start_page | 427 |
| container_title | Medical journal of Indonesia |
| container_volume | 29 |
| creator | Aisyi, Mururul Syarif, Ayu Hutami Asih, Nur Kosasih, Agus |
| description | Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are limited, no case has been reported. We describe TKI-resistance of a pediatric CML case in Dharmais Cancer Hospital, Jakarta. A 17-year-old boy presented with loss of complete hematologic response after 4 years of imatinib treatment. Diagnosis of relapsed CML with blast crisis was confirmed, and nilotinib was given accordingly. He achieved hematological and optimal response after 2 weeks and 3 months of treatment, respectively. However, in the 12-month evaluation, he failed to achieve major molecular response and acquired the second resistance to TKI. Since imatinib resistance marks the poor prognosis, initial optimal response of nilotinib treatment remains inconclusive to predict the final outcome. |
| doi_str_mv | 10.13181/mji.cr.203765 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2694944659</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2694944659</sourcerecordid><originalsourceid>FETCH-LOGICAL-c267t-dfbc27ac85c9ea83a17ce8b17125221a8ebf23aae04218916b97ee3953904c1f3</originalsourceid><addsrcrecordid>eNotkD1rwzAYhEVpoSHN2lnQ2a4-LEvqVkK_INAlHToJWXlNlMSW-8oZ8u_rNJ0OjuOOewi556zkkhv-2O1iGbAUTOpaXZGZEEoUhhl5TWbMKFlwreUtWeQcG8alYbUSYka-1ydMOfZA97H3GWjst7GJY0KKkGMefR_OJh1gE_2IMdCwxdRP2p3gkOKGHuC4hy76J-ppOFcgDAnHO3LT-kOGxb_Oydfry3r5Xqw-3z6Wz6siiFqPxaZtgtA-GBUseCM91wFMwzWfDgjuDTStkN4DqwQ3lteN1QDSKmlZFXgr5-Th0jtg-jlCHt0uHbGfJp2obWWrqlZ2SpWXVJjuZoTWDRg7jyfHmfsj6CaCLqC7EJS_Ga5lxg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2694944659</pqid></control><display><type>article</type><title>Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report</title><source>EZB Electronic Journals Library</source><creator>Aisyi, Mururul ; Syarif, Ayu Hutami ; Asih, Nur ; Kosasih, Agus</creator><creatorcontrib>Aisyi, Mururul ; Syarif, Ayu Hutami ; Asih, Nur ; Kosasih, Agus</creatorcontrib><description>Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are limited, no case has been reported. We describe TKI-resistance of a pediatric CML case in Dharmais Cancer Hospital, Jakarta. A 17-year-old boy presented with loss of complete hematologic response after 4 years of imatinib treatment. Diagnosis of relapsed CML with blast crisis was confirmed, and nilotinib was given accordingly. He achieved hematological and optimal response after 2 weeks and 3 months of treatment, respectively. However, in the 12-month evaluation, he failed to achieve major molecular response and acquired the second resistance to TKI. Since imatinib resistance marks the poor prognosis, initial optimal response of nilotinib treatment remains inconclusive to predict the final outcome.</description><identifier>ISSN: 0853-1773</identifier><identifier>EISSN: 2252-8083</identifier><identifier>DOI: 10.13181/mji.cr.203765</identifier><language>eng</language><publisher>Jakarta: Faculty of Medicine Universitas Indonesia</publisher><subject>Binding sites ; Blood platelets ; Bone marrow ; Cancer ; Case reports ; Cell cycle ; Cell division ; FDA approval ; Hematology ; Kinases ; Leukemia ; Medical prognosis ; Patients ; Pediatrics ; Signal transduction</subject><ispartof>Medical journal of Indonesia, 2020-12, Vol.29 (4), p.427-30</ispartof><rights>2020. This work is licensed under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c267t-dfbc27ac85c9ea83a17ce8b17125221a8ebf23aae04218916b97ee3953904c1f3</citedby><cites>FETCH-LOGICAL-c267t-dfbc27ac85c9ea83a17ce8b17125221a8ebf23aae04218916b97ee3953904c1f3</cites><orcidid>0000-0001-9754-5696</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Aisyi, Mururul</creatorcontrib><creatorcontrib>Syarif, Ayu Hutami</creatorcontrib><creatorcontrib>Asih, Nur</creatorcontrib><creatorcontrib>Kosasih, Agus</creatorcontrib><title>Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report</title><title>Medical journal of Indonesia</title><description>Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are limited, no case has been reported. We describe TKI-resistance of a pediatric CML case in Dharmais Cancer Hospital, Jakarta. A 17-year-old boy presented with loss of complete hematologic response after 4 years of imatinib treatment. Diagnosis of relapsed CML with blast crisis was confirmed, and nilotinib was given accordingly. He achieved hematological and optimal response after 2 weeks and 3 months of treatment, respectively. However, in the 12-month evaluation, he failed to achieve major molecular response and acquired the second resistance to TKI. Since imatinib resistance marks the poor prognosis, initial optimal response of nilotinib treatment remains inconclusive to predict the final outcome.</description><subject>Binding sites</subject><subject>Blood platelets</subject><subject>Bone marrow</subject><subject>Cancer</subject><subject>Case reports</subject><subject>Cell cycle</subject><subject>Cell division</subject><subject>FDA approval</subject><subject>Hematology</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Signal transduction</subject><issn>0853-1773</issn><issn>2252-8083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNotkD1rwzAYhEVpoSHN2lnQ2a4-LEvqVkK_INAlHToJWXlNlMSW-8oZ8u_rNJ0OjuOOewi556zkkhv-2O1iGbAUTOpaXZGZEEoUhhl5TWbMKFlwreUtWeQcG8alYbUSYka-1ydMOfZA97H3GWjst7GJY0KKkGMefR_OJh1gE_2IMdCwxdRP2p3gkOKGHuC4hy76J-ppOFcgDAnHO3LT-kOGxb_Oydfry3r5Xqw-3z6Wz6siiFqPxaZtgtA-GBUseCM91wFMwzWfDgjuDTStkN4DqwQ3lteN1QDSKmlZFXgr5-Th0jtg-jlCHt0uHbGfJp2obWWrqlZ2SpWXVJjuZoTWDRg7jyfHmfsj6CaCLqC7EJS_Ga5lxg</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Aisyi, Mururul</creator><creator>Syarif, Ayu Hutami</creator><creator>Asih, Nur</creator><creator>Kosasih, Agus</creator><general>Faculty of Medicine Universitas Indonesia</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BVBZV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-9754-5696</orcidid></search><sort><creationdate>20201201</creationdate><title>Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report</title><author>Aisyi, Mururul ; Syarif, Ayu Hutami ; Asih, Nur ; Kosasih, Agus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c267t-dfbc27ac85c9ea83a17ce8b17125221a8ebf23aae04218916b97ee3953904c1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Binding sites</topic><topic>Blood platelets</topic><topic>Bone marrow</topic><topic>Cancer</topic><topic>Case reports</topic><topic>Cell cycle</topic><topic>Cell division</topic><topic>FDA approval</topic><topic>Hematology</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Signal transduction</topic><toplevel>online_resources</toplevel><creatorcontrib>Aisyi, Mururul</creatorcontrib><creatorcontrib>Syarif, Ayu Hutami</creatorcontrib><creatorcontrib>Asih, Nur</creatorcontrib><creatorcontrib>Kosasih, Agus</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East & South Asia Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical journal of Indonesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aisyi, Mururul</au><au>Syarif, Ayu Hutami</au><au>Asih, Nur</au><au>Kosasih, Agus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report</atitle><jtitle>Medical journal of Indonesia</jtitle><date>2020-12-01</date><risdate>2020</risdate><volume>29</volume><issue>4</issue><spage>427</spage><epage>30</epage><pages>427-30</pages><issn>0853-1773</issn><eissn>2252-8083</eissn><abstract>Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are limited, no case has been reported. We describe TKI-resistance of a pediatric CML case in Dharmais Cancer Hospital, Jakarta. A 17-year-old boy presented with loss of complete hematologic response after 4 years of imatinib treatment. Diagnosis of relapsed CML with blast crisis was confirmed, and nilotinib was given accordingly. He achieved hematological and optimal response after 2 weeks and 3 months of treatment, respectively. However, in the 12-month evaluation, he failed to achieve major molecular response and acquired the second resistance to TKI. Since imatinib resistance marks the poor prognosis, initial optimal response of nilotinib treatment remains inconclusive to predict the final outcome.</abstract><cop>Jakarta</cop><pub>Faculty of Medicine Universitas Indonesia</pub><doi>10.13181/mji.cr.203765</doi><tpages>-396</tpages><orcidid>https://orcid.org/0000-0001-9754-5696</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0853-1773 |
| ispartof | Medical journal of Indonesia, 2020-12, Vol.29 (4), p.427-30 |
| issn | 0853-1773 2252-8083 |
| language | eng |
| recordid | cdi_proquest_journals_2694944659 |
| source | EZB Electronic Journals Library |
| subjects | Binding sites Blood platelets Bone marrow Cancer Case reports Cell cycle Cell division FDA approval Hematology Kinases Leukemia Medical prognosis Patients Pediatrics Signal transduction |
| title | Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T18%3A52%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tyrosine%20kinase%20inhibitor%20resistance%20in%20pediatric%20chronic%20myeloid%20leukemia:%20a%20case%20report&rft.jtitle=Medical%20journal%20of%20Indonesia&rft.au=Aisyi,%20Mururul&rft.date=2020-12-01&rft.volume=29&rft.issue=4&rft.spage=427&rft.epage=30&rft.pages=427-30&rft.issn=0853-1773&rft.eissn=2252-8083&rft_id=info:doi/10.13181/mji.cr.203765&rft_dat=%3Cproquest_cross%3E2694944659%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2694944659&rft_id=info:pmid/&rfr_iscdi=true |